WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that multiple abstracts were selected for oral and poster presentations at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer to be held on March 18-21, 2022 in Phoenix, Arizona.
Full results from the pivotal SORAYA trial of mirvetuximab soravtansine (mirvetuximab) in ovarian cancer will be shared in a late-breaking oral presentation.
Title: Efficacy and Safety of Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer with High Folate Receptor Alpha Expression: Results from the SORAYA Study
Presenter: Dr. Ursula Matulonis, Chief of the Division of Gynecologic Oncology at the Dana-Farber Cancer Institute, Professor of Medicine at the Harvard Medical School, and SORAYA Co-Principal Investigator
Session: Scientific Plenary IV: Late-Breaking Abstracts
Session Date: Saturday, March 19, 2022
Session Time: 4:15 pm to 5:45 pm MST
Trial in progress posters from ImmunoGen’s MIRASOL and PICCOLO trials of mirvetuximab in ovarian cancer and a Phase 2 investigator-sponsored combination trial of mirvetuximab with carboplatin in the neoadjuvant setting will also be presented.
Title: MIRASOL: A Randomized, Open-Label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor Alpha Expression
Presenter: Dr. Kathleen Moore, Director of the Oklahoma TSET Phase I Program, Associate Professor of the Section of Gynecologic Oncology at The University of Oklahoma College of Medicine, and MIRASOL Principal Investigator
Title: PICCOLO: An Open-Label, Single Arm, Phase 2 Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor Alpha Expression
Presenter: Dr. Angeles Alvarez Secord, Professor of Obstetrics and Gynecology at Duke University School of Medicine in Durham, North Carolina
Title: Single-Arm Phase II Trial of Carboplatin and Mirvetuximab Soravtansine as Neoadjuvant Chemotherapy for Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer who are Folate Receptor α Positive
Presenter: Dr. Jhalak Dholakia, Department of Obstetrics and Gynecology at the University of Alabama
Final data from the mirvetuximab plus bevacizumab platinum-agnostic combination study, which were originally shared at ASCO 2021, will be re-presented.
Title: Mirvetuximab Soravtansine, a Folate Receptor Alpha-Targeting Antibody Drug Conjugate in Combination with Bevacizumab in Patients with Platinum-Agnostic Ovarian Cancer: Final Analysis
Session: Seminal Abstracts: The Best of ASCO, ESMO, IGCS, and ESGO
Presenter: Dr. David O’Malley, Professor, Director of Gynecologic Oncology and the Director of the Division of Gynecologic Oncology at The Ohio State University and the James Cancer Center
Additional information can be found on the SGO website.
INVESTOR EVENT INFORMATION
ImmunoGen will hold an investor event to discuss the SORAYA data, featuring a roundtable with key opinion leaders, on Sunday, March 20 at 7:30 am MST/10:30 am EDT in the Moly Meeting Room at the Westin Phoenix Downtown. To access the live event by phone, dial (877) 621-5803; the conference ID is 1986619. The event may also be accessed via webstream on the Investors and Media section of the Company’s website, www.immunogen.com. Following the call, a replay will be available at the same location.
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.
Learn more about who we are, what we do, and how we do it at www.immunogen.com.
This press release includes forward-looking statements. These statements include, but are not limited to, ImmunoGen's expectations related to: the potential benefits of the Company's product candidates and the timing and presentation of preclinical and clinical data on the Company's product candidates. Various factors could cause ImmunoGen's actual results to differ materially from those discussed or implied in the forward-looking statements, and you are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this release. Factors that could cause future results to differ materially from such expectations include, but are not limited to: the timing and outcome of the Company's preclinical and clinical development processes; the difficulties inherent in the development of novel pharmaceuticals, including uncertainties as to the timing, expense, and results of preclinical studies, clinical trials, and regulatory processes; the timing and outcome of the Company's anticipated interactions with regulatory authorities; obtaining, maintaining, and protecting the Company's intellectual property; the Company's ability to financially support its product programs; risks and uncertainties associated with the scale and duration of the COVID-19 pandemic and the resulting impact on ImmunoGen's industry and business; and other factors as set forth in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2021, and other reports filed with the Securities and Exchange Commission.